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ABSTRACT 
Background: Although, the exact pathophysiology of preeclampsia is unknown, activation 
of monocytes and macrophages (monocyte/macrophage activation) is suggested to have a 
rolein the immunopathology of preeclampsia. Soluble CD163 (sCD163) is considered a 
specific marker of monocyte/macrophage activation. Nonetheless, investigations addressing 
sCD163 in cases preeclamptic women are needed.  
Objectives: To investigate maternal and umbilical cord levels of sCD163 in women with 
preeclampsia. 
Materials and Methods: A case – control study was conducted at the labour ward of Qassim 
Maternity Hospital, Kingdom of Saudi Arabia during the period of March -September 2015. 
Forty five cases of preeclamptic women and an equal number of healthy pregnant women 
were controls. Obstetrics and medical history was gathered using questionnaire.  
sCD163 levels were measured using ELISA. 
Results: The two groups (45 in each arm of the study) were matched in their age and parity. 
Thirty- three of the 45 cases were patients with severe preeclampsia.  
The median (interquartile) levels of both maternal [32.70(18.9 – 47.0) vs. 52.5(33.7–
74.8)ng/ml, P= 0.001] and cord [12.30(10.9– 23.10) vs. 52.4(20.80 – 63.0) ng/ml, P< 0.001] 
sCD163 were significantly lower in the preeclamptic cases compared to the controls.  
There was a significant direct correlation between the maternal and umbilical cord level of 
sCD163. Both maternal and umbilical cord sCD163 levels were inversely correlated with 
birth weight.  
Conclusion:  The current study showed significantly lower maternal and cord sCD163 levels 
in women with preeclampsia as compared to controls. Moreover, there was a significant 
direct correlation between the maternal and umbilical cord level of sCD163 on one hand and 
birth weight on the other. 
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reeclampsia is big  health  problem  
where it complicates 3–8% of all 
pregnancies and manifests clinically 
after the 20 weeks of gestation1. 
Preeclampsia is a serious medical disorder; 
it can lead to convulsion and maternal 
death2-5.  
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Although the exact pathophysiology of 
preeclampsia is not yet fully understood, 
certain factors have been attributed to. 
These include changes in placental 
perfusion, changes in the immune system, 
and endothelial dysfunction6,7.   
Macrophages which are antigen-presenting 
___________________________________________________ 
*Correspondence to:Prof. Ishag Adam Department 
of Obstetrics and Gynaecology, Medical College, 




Alsheeha et al.Soluble CD163 is Lower In Maternal and Umb. Cord Serum In Preeclampsia 
 
© Sudan JMS Vol. 11, No.3. Sept 2016                    130 
cells, account for the second most 
numerous type of immune cellsin the 
human deciduas of pregnancy and act as 
immune-modulatory cells8,9. Involvement 
of different types of macrophages have 
recently been postulated in  the 
pathogenesis of preeclampsia10,11. Soluble 
CD163 (sCD163) is a macrophage 
scavenging receptor. It is a mononuclear 
phagocyte–restricted cell surface 
glycoprotein antigen present on type 2 
macrophages (M2 cells) which exerts an 
anti-inflammatory function12.  
Macrophages stimulated via Th1 
cytokines/chemokiness polarize toward 
pro-inflammatory type 1 macrophages 
(M1 cells). These cells can defend against 
utero-placental infections, but they have 
no  role in the tolerance of the fetus11. 
Recent research studies suggested a role 
for sCD163 in the pathogenesis of 
preeclampsia especially when it is 
associated with intrauterine growth 
restriction13-17. However,  the  results of 
these studies were  not concordant. Thus,  
while some results showed low levels of 
expression of sCD163 in preeclampsia, 
others showed , the other showed no or 
high levels of expression. The current 
study  was conducted to  investigate 
maternal and umbilical  cord level of s CD 
163 in women  with  preeclampsia  and the 
correlations (if any) between  sCD163, 
maternal  hemoglobin  and birth weight.  
MATERIALS AND METHODS: 
A case control study was conducted at the 
labour ward of QassimMaternity Hospital, 
Kingdom of Saudi Arabia during the 
period of March-September 2015. 
Qassim.Qassim Maternity Hospital is a 
tertiary hospital for referring cases with 
high risk pregnancy.  Cases were of 
women with preeclampsia which isdefined 
as the occurrence of hypertension (systolic 
blood pressure 140 mm Hg or diastolic 
blood pressure  90 mm Hg) in the second 
half of pregnancy (after 20 weeks) and 
proteinuria (presence of 300 mg or more of 
protein in 24 h urine sample or 2+ on 
dipstick).  Preeclampsia is considered mild 
or severe according to the diastolic blood 
pressure - mild if < 110 mmHg, or severe 
if 110 mmHg18. Healthy women were 
taken as controls. Thyroid disease, 
hypertension, renal disease, diabetes and 
liver disease were the exclusion criteria.  
After signing an informed consent, 
medical and obstetrics history (age, parity, 
and gestational age) was gathered using a 
questionnaire.  
Body mass index (BMI) was computed via 
weight in kilograms divided by the square 
of height in meters which were measured 
of each participant. Maternal hemoglobin 
was measured and the results recorded. 
The birth weight was measure and 
recorded following the delivery.  
Then maternal  and umbilical cord blood 
(5 mls) were taken from each woman (case 
or control), allowed to clot, centrifuged, 
and stored at 20°C until analyses was 
performed using  Ultra-Sensitive sCD163 
ELISA KIT, (bioactivadiagnostica GmbH 
- Bad Homburg, Germany). The 
manufacturers` instructions were followed.  
A total sample size of 45 participants in 
each arm of the study was calculated to 
have the mean  difference of the sCD163 
and that would provide 80% power to 
detect a 5% difference at  = 0.05, with an 
assumption that complete data might not 
be available for 10% of participants. 
Statistics: 
SPSS for Windows (version 20.0) was 
used for data analyses. 
Continuousvariables were checked for 
normality and their difference was 
compared between the cases and controls 
using T-test and Mann-Whitney U when 
the data were normally and not normally 
distributed, respectively. Spearman 
correlation was performed between 
maternal and umbilical cord sCD163 level, 
and birth weight andhaemoglobin level. P 
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< 0.05 was considered statistically 
significant. 
RESULTS: 
While there was no  significant difference 
in  the  age,  parity and BMI between  the 
two groups ( 45 women in  each arm),  
gestational  age and birth weight were 
significantly lower in the cases,  table1 .   
Median (interquartile) levels of both 
maternal [32.70(18.9 – 47.0) vs. 
52.5(33.7–74.8)ng/ml, P= 0.001] and cord 
[12.30(10.9– 23.10) vs. 52.4 (20.80 – 
63.0)ng/ml, P< 0.001] sCD163 were 
significantly lower in the cases compared 
to  the controls. While the  sCD163 level 
in cord blood was significantly lower  than  
that of  maternal blood level in  the 
preeclamptic cases,  there was no such a 
significant  difference  between them in  
the  controls (Table 2). There was a 
significant positive correlationbetween the 
maternal and umbilicalcord level of 
sCD163. Both maternaland umbilical cord 
sCD163 levelswere inversely correlated 
with birth weight (Table 3).
Table 1: Basic characteristics of the studied cases and controls  
Variable  Cases (n=45) Controls  (n=45) P 
Age,  years 27.5 (3.8) 28.1(4.2) 0.504 
Parity 2.3(1.8) 2..6(1.4) 0.521 
Gestational  age, weeks 37.2(1.2) 38.1(1.1) 0.001 
Body mass index, Kg/m2 24.3(2.1) 24.4(2.4) 0.833 
Birth  weight, g 2346.6(2055.0) 2864.4(3747.0) <0.001 
Table 2: Median (interquartile range) of maternal and umbilical cord soluble CD 163 levels in 
the case and controls  
Variable  Cases (n=45) Controls (n=45) P 
Maternal  s CD 163, ng/ml 32.70(18.9 – 47.0) 52.5(33.7–74.8) 0.001 
Umbilical cord  sCD163,ng/ml 12.30(10.9– 23.10) 52.4(20.80– 63.0) <0.001 
P  < 0.001 0.304  
 
Figure 1: Median (interquartile range) of maternal soluble CD 163 levels in the case and 
controls.
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DISCUSSION: 
The main  findings of the current study  
were; the significantly lower sCD163 in  
women with  preeclampsia as compared to 
controls   and an inverse correlation 
between  sCD163 levels and birth  weight. 
Our results are consistent with the 
previous finings where expression of 
CD163 was significantly lower in 58 
women with preeclampsia compared with 
the 52 controls women that were matched 
for gestational age4. It has recently been 
reported that expression of CD163 was 
significantly lower in preeclamptic women 
compared with controls13.
Table 3: Spearman correlation between the maternal, cord soluble 163 and birth weight  
Variable  Maternal s 163 
r P 
Cord s 163 
r P 
Birth  weight 
r P 
Cord s 163 0.232      0.028 —        — - 0.284  0.007     
Birth  weight -0.333   0.001 - 0.284  0.007     —    — 
Maternal hemoglobin 0.280     0.061 0.350     0.018 0.007     0.964 
 
 
Figure 2: Median (interquartile range) of umbilical cord soluble CD 163 levels in the case 
and controls.
On the other hand there are reports that are 
discordant to ours. Thus  Schonkeren et al. 
(2011) (Schonkeren et al. 2011) reported 
that  CD163 expression increased 
significantly in preterm preeclamptic 
decidua basalis compared with preterm 
control pregnancies where as Kronborg et
al (2007)observed that there was no 
significant difference in  the serum level of 
sCD163 between pregnant and non-
pregnant women, and that sCD163 level 
did not increase from week 18 to 38  and 
there was a tendency towards higher 
sCD163 in week 38 in preeclamptic 
women compared to healthy women. 
Likewise  it has  recently been observed 
that CD163 level showed a small but not 
statistically significant (p-value=0.37) 
increase in women with  preeclampsia 
compared to  controls17. 
The current study showed no significant 
correlation between maternal hemoglobin 
and sCD163 but showed a significant 
correlation between cord sCD163 and 
hemoglobin. Recently Chua et  al.,  
observed   an    inverse    association       of  
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sCD163, with haemoglobin levels in 
placental malaria.,  which  is another 
disease  charactreized by 
macrophage/monocyte infiltration19. 
CD163 is a key regulator of macrophage 
function and act  in  scavenging of free 
haemoglobin20.  Free hemoglobin, a highly 
cytotoxic compound, has been reported to 
be elevated in  preeclampsia21,22. 
CONCLUSION:   
The current study showed significantly 
lower   sCD163 levels (in both maternal 
and cord blood) in women with 
preeclampsia. There was a significant 
positive correlation between the maternal, 
umbilical  cord level of sCD163  and birth  
weight 
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